Shares of H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) fell 49.5% during mid-day trading on Monday . The stock traded as low as $2.02 and last traded at $2.02. 400 shares were traded during trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Trading Down 49.5 %
The stock has a 50-day moving average of $2.02 and a 200 day moving average of $2.02.
H-CYTE Company Profile
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Stories
- Five stocks we like better than H-CYTE
- Best Stocks Under $10.00
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- Growth Stocks: What They Are, What They Are Not
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- How Can Investors Benefit From After-Hours Trading
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
